Xenon Pharmaceuticals Inc.
XENE
Classificação em ações
#4430
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Preço da ação
$36.18
Valor de mercado
$3.50B
Variação (1 dia)
-0.25%
Variação (1 ano)
-15.94%
País
CA
Negociar Xenon Pharmaceuticals Inc. (XENE)
Categoria
Healthcare
Receita da Xenon Pharmaceuticals Inc. (XENE)
Receita em Jun 2026 TTM: 0.00
De acordo com os últimos relatórios financeiros da Xenon Pharmaceuticals Inc., a receita atual da empresa (TTM) é 0.00. Em 2023, a empresa obteve uma receita de 0.00 uma diminuição em relação a a receita do ano 2022, que foi de $9.43M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Xenon Pharmaceuticals Inc. de 2011 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $9.43M | -48.83% |
| 2021 | $18.44M | -42.68% |
| 2020 | $32.17M | 371.02% |
| 2019 | $6.83M | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | $311.00K | -82.75% |
| 2016 | $1.80M | -88.43% |
| 2015 | $15.58M | -45.09% |
| 2014 | $28.37M | 3.71% |
| 2013 | $27.36M | 91.19% |
| 2012 | $14.31M | 106.82% |
| 2011 | $6.92M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
